Regenacy Pharmaceuticals, Inc.

Regenacy Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral, isoform-selective histone deacetylase (HDAC) inhibitors to restore normal protein function. Spun out in 2016 from the assets of Acetylon Pharmaceuticals after Celgene's acquisition, Regenacy's lead drug ricolinostat (ACY-1215) is a selective HDAC6 inhibitor in clinical development for painful diabetic peripheral neuropathy and other peripheral neuropathies, with an additional portfolio of HDAC1,2 inhibitors targeting blood diseases and cognitive disorders.